RESEARCH TRIANGLE PARK–ChemCodes plans to hire a a vice president of medicinal chemistry and additional scientists to ramp up development of potential drug compounds within the company, it says.

John Didsbury, ChemCodes president and chief executive officer, says the company will hire new people to enhance its ability to find and develop lead clinical compounds interesting to the pharmaceutical industry.

ChemCodes is currently working on internal programs to develop drugs for treatment of cancer, diabetes and inflammation.

The company’s primary stragegy is to find “fast follower” products that are novel analogues of marketed medicines and compound renovation products. The later are chemical improvements of early discovery compounds.

The venture-backed company says it will continue to establish selective corporate partnerships as well.

ChemCodes uses a proprietary high throughput chemistry driven drug discovery technology it licensed from GlaxoSmithKline.